What is Wedbush’s Estimate for RCUS FY2029 Earnings?
Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Arcus Biosciences in a note issued to investors ...
Q1 Earnings Forecast for RCUS Issued By HC Wainwright
Research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Arcus Biosciences in a report issued on ...
BioPharma Dive2d
Sanofi reaches consumer health deal; Supernus antidepressant fails study
The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...
Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate
Precision BioSciences reports early PBGENE-HBV trial data showing safety and antiviral activity in chronic Hepatitis B patients, with more results expected in 2025.
BioSpace2d
Gilead Passes on Option for Arcus’ Cancer Drug Despite Strong Early Data
The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...
Business Wire3d
Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo g ...
Arcus Biosciences price target lowered to $17 from $22 at BofA
BofA lowered the firm’s price target on Arcus Biosciences (RCUS) to $17 from $22 and keeps a Neutral rating on the shares following Gilead’s ...
2RCUS : Arcus Biosciences Shares Are Down Today: What's Going On?
Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock ...